Why the study?
Rivaroxaban is an alternative to warfarin for thromboembolism prevention in AF, but there has been concern regarding major bleeding risk, particularly in Asian patients.
Does rivaroxaban reduce thromboembolic events and major bleeding compared to warfarin in Korean patients with non-valvular atrial fibrillation?
Does rivaroxaban reduce thromboembolic events and major bleeding compared to warfarin in Korean patients with non-valvular atrial fibrillation?
No takes yet. Share an insight, caveat, or question.
May support rivaroxaban preference for bleeding reduction in Korean NVAF; hypothesis-generating and leaves randomized confirmation open.
Jeong et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: